While the Syk inhibitor attenuated the inflammatory responses from leaky gut–derived endotoxemia and glucanemia, the severity of leaky gut in FcγRIIb−/− mice was not altered by the inhibitor [42, 43]. The gene discussed is SYK; the disease is serum lipopolysaccharide activity.